CA3100171A1 - Blood biomarkers of stroke - Google Patents

Blood biomarkers of stroke Download PDF

Info

Publication number
CA3100171A1
CA3100171A1 CA3100171A CA3100171A CA3100171A1 CA 3100171 A1 CA3100171 A1 CA 3100171A1 CA 3100171 A CA3100171 A CA 3100171A CA 3100171 A CA3100171 A CA 3100171A CA 3100171 A1 CA3100171 A1 CA 3100171A1
Authority
CA
Canada
Prior art keywords
stroke
signature
subject
sample
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3100171A
Other languages
English (en)
French (fr)
Inventor
Serge Timsit
Emmanuelle Genin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Etablissement Francais du Sang
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Etablissement Francais du Sang
Centre Hospitalier Regional et Universitaire de Brest
Univerdite de Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Etablissement Francais du Sang, Centre Hospitalier Regional et Universitaire de Brest, Univerdite de Bretagne Occidentale filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of CA3100171A1 publication Critical patent/CA3100171A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA3100171A 2018-05-16 2019-05-16 Blood biomarkers of stroke Pending CA3100171A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305600 2018-05-16
EP18305600.1 2018-05-16
PCT/EP2019/062653 WO2019219831A1 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Publications (1)

Publication Number Publication Date
CA3100171A1 true CA3100171A1 (en) 2019-11-21

Family

ID=62386311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3100171A Pending CA3100171A1 (en) 2018-05-16 2019-05-16 Blood biomarkers of stroke

Country Status (13)

Country Link
US (1) US12247257B2 (https=)
EP (1) EP3794355A1 (https=)
JP (2) JP7463351B2 (https=)
KR (1) KR20210049026A (https=)
CN (1) CN112424609A (https=)
AU (1) AU2019270404B2 (https=)
BR (1) BR112020023259A2 (https=)
CA (1) CA3100171A1 (https=)
IL (1) IL278666B2 (https=)
MA (1) MA52617A (https=)
MX (1) MX2020012297A (https=)
SG (1) SG11202011369VA (https=)
WO (1) WO2019219831A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220093267A1 (en) * 2019-01-22 2022-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Noninvasive real-time patient-specific assessment of stroke severity
CN114107487B (zh) * 2021-12-23 2024-01-09 太原市精神病医院 一种可用于诊断脑卒中的产品
JP2023111774A (ja) * 2022-01-31 2023-08-10 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
CN116705296B (zh) * 2023-06-06 2024-09-13 中国科学院深圳先进技术研究院 一种基于常规mri序列对gbm患者进行风险分层的方法及系统
WO2025151599A1 (en) * 2024-01-09 2025-07-17 Morehouse School Of Medicine Rna-based method for stroke assessment and treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU2002241520A1 (en) * 2000-11-28 2003-03-03 University Of Cincinnati Blood assessment of injury
US9005891B2 (en) 2009-11-10 2015-04-14 Genomic Health, Inc. Methods for depleting RNA from nucleic acid samples
US9410204B2 (en) 2012-01-07 2016-08-09 The Regents Of The University Of California Biomarkers for diagnosing ischemia
US20150274815A1 (en) * 2012-09-25 2015-10-01 The United States of America, as represented by the Secretary, Department of Health & Human Servic Treatment of central nervous system (cns) injury
JP2016507235A (ja) * 2013-02-01 2016-03-10 ウエストバージニア ユニバーシティＷｅｓｔ Ｖｉｒｇｉｎｉａ Ｕｎｉｖｅｒｓｉｔｙ 脳卒中症状の発症の時点を決定するためのバイオマーカーアルゴリズムおよび方法
US11021750B2 (en) * 2013-10-13 2021-06-01 The Research Foundation For State University Of Newyork Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
CN108291330A (zh) * 2015-07-10 2018-07-17 西弗吉尼亚大学 卒中和卒中严重性的标志物
US20190311789A1 (en) * 2016-10-03 2019-10-10 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption

Also Published As

Publication number Publication date
MA52617A (fr) 2021-03-24
KR20210049026A (ko) 2021-05-04
EP3794355A1 (en) 2021-03-24
AU2019270404B2 (en) 2025-04-17
SG11202011369VA (en) 2020-12-30
AU2019270404A2 (en) 2020-12-17
IL278666B1 (en) 2025-02-01
US20210214793A1 (en) 2021-07-15
JP2021523744A (ja) 2021-09-09
AU2019270404A1 (en) 2020-12-10
MX2020012297A (es) 2021-03-25
JP2024075761A (ja) 2024-06-04
IL278666A (en) 2020-12-31
BR112020023259A2 (pt) 2021-02-23
US12247257B2 (en) 2025-03-11
JP7463351B2 (ja) 2024-04-08
WO2019219831A1 (en) 2019-11-21
IL278666B2 (en) 2025-06-01
CN112424609A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
US12247257B2 (en) Blood biomarkers of stroke
US9803243B2 (en) Biomarkers for diagnosis of stroke and its causes
US10859573B2 (en) Nourin molecular biomarkers diagnose angina patients with negative troponin
Chen et al. Assessment of acute pancreatitis severity via determination of serum levels of hsa-miR-126-5p and IL-6
JP2023501760A (ja) 子癇前症に特異的な循環ｒｎａシグネチャー
Baos et al. Biomarkers associated with disease severity in allergic and nonallergic asthma
US20160258019A1 (en) Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
US20200188356A1 (en) Novel Circular RNA Biomarkers for Heart Failure
JP6784673B2 (ja) 膵臓がんに冒された患者の生存予後を判断する方法
US20160244845A1 (en) Method for determining the prognosis of pancreatic cancer
CN111315897B (zh) 用于黑素瘤检测的方法
US20140221235A1 (en) Biomarker algorithm for determining the time of stroke symptom onset and method
JP2023157965A (ja) アトピー性皮膚炎の検出方法
KR102184840B1 (ko) 외상 후 스트레스 장애 진단 또는 예측용 바이오마커 및 그의 용도
RU2821748C2 (ru) Способы диагностики инсульта, эффективности терапии, определения риска инсульта
Tang et al. Clinical value of serum LncRNA MIAT in early diagnosis and prognosis assessment of traumatic brain injury
US20210087634A1 (en) Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger rna
US20240125766A1 (en) Method for determining suitability of a subject to anti tnf alpha therapy
JP7847450B2 (ja) アトピー性皮膚炎の症度悪化の検出方法
JP7847451B2 (ja) アトピー性皮膚炎による皮膚痒みの症度悪化の検出方法
KR20250068515A (ko) 파킨슨병의 진단, 예후 예측, 또는 치료용 턱밑샘 조직 바이오마커, 및 이를 이용한 파킨슨병 진단, 또는 예후 예측 방법, 및 파킨슨병 치료 물질 스크리닝 방법
JP2024161911A (ja) アトピー性皮膚炎の重症度の検出方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240506

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250411

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725